CD274 and gastric cancer: Based on the above clinical outcomes, The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer (2021) only recommend pembrolizumab single-drug first-line therapy as a grade III recommendation (evidence 1B) for patients with PD-L1 CPS ≥1 (17).